Aim immunotech announces ethics committee approval to commence phase 1 clinical study of ampligen as an intranasal therapy

Ocala, fla., feb. 16, 2021 (globe newswire) -- aim immunotech inc. (nyse american: aim) today announced that it has received approval from the required ethics committee in the netherlands to commence its phase 1 clinical study on the safety of aim's drug ampligen as an intranasal therapy, a critical step in the company's ongoing efforts to develop ampligen as a potential prophylaxis or treatment for covid-19 and other respiratory viral diseases.
AIM Ratings Summary
AIM Quant Ranking